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Abstract
Since their discovery in the late 1970’s, protein kinase C (PKC) isozymes represent one of the 
most extensively studied signaling kinases. PKCs signal through multiple pathways and control 
the expression of genes relevant for cell cycle progression, tumorigenesis and metastatic 
dissemination. Despite the vast amount of information concerning the mechanisms that control 
PKC activation and function in cellular models, the relevance of individual PKC isozymes in the 
progression of human cancer is still a matter of controversy. Although the expression of PKC 
isozymes is altered in multiple cancer types, the causal relationship between such changes and the 
initiation and progression of the disease remains poorly defined. Animal models developed in the 
last years helped to better understand the involvement of individual PKCs in various cancer types 
and in the context of specific oncogenic alterations. Unraveling the enormous complexity in the 
mechanisms by which PKC isozymes impact on tumorigenesis and metastasis is key for 
reassessing their potential as pharmacological targets for cancer treatment.
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Introduction
Protein kinase C (PKC), a prototypical class of serine/threonine kinases, exemplifies specific 
signaling molecules that link multiple cellular processes to cancer. Originally identified as a 
cellular receptor for the phorbol ester tumor promoters more than 30 years ago [1–2], PKC 
became the subject of intense studies by academic laboratories and pharmaceutical 
companies (>50,000 citations in PubMed, which is even more than other ABC kinases such 
as PKA or PKB/Akt). Extensive work established these kinases as pleiotropic regulators of 
cell function, including proliferation, differentiation, survival and motility [3]. To date, it is 
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clear that PKCs are associated with a number of diseases, including cancer, cardiovascular 
dysfunctions and metabolic disorders. The complexity in PKC signaling arises from the fact 
that PKC is a multifamily of structurally related kinases with diverse biological functions. 
Indeed, mammalian PKCs encompass 10 members that represent the products of 9 different 
genes located in different chromosomes. PKC isozymes have been classified into three 
groups: “conventional” or “classical” PKCs (cPKCs) that are composed of PKCα, two splice 
variants of PKCβ (PKCβI and PKCβII) and PKCγ; “novel” PKCs (nPKCs), a group that 
includes PKCδ, PKCε, PKCη, and PKCθ; and “atypical” PKCs (aPKCs) ζ and ι (λ). cPKCs 
and nPKCs are activated by diacylglycerol (DAG), a lipid second messenger transiently 
generated upon stimulation of membrane receptors such as tyrosine-kinase and G-protein-
coupled receptors. DAG mimics the action of phorbol esters, as they bind to the C1 domains 
in the regulatory region. Only the cPKCs are calcium-sensitive, as they have a calcium-
binding C2 domain (the C2 domain in nPKCs is calcium-insensitive). aPKCs display unique 
regulatory properties: they are unable to bind DAG or calcium and rather depend on protein-
protein interactions and phosphorylation for their activation [3] (Fig. 1).
In the last years we have witnessed major advances in our understanding of the roles of 
PKCs in tumor development and progression, including in late stages of the disease and 
metastasis. This review summarizes the knowledge on PKC isozymes in cancer progression 
and highlights the most recent advances in the field, particularly using genetically modified 
mouse models in the context of specific oncogenic alterations.
PKC isozyme expression in cancer: chance or causality?
Expression levels of PKC isozymes change in neoplastic diseases. The overall picture is 
however confusing, partly due to potential issues of antibody specificity in 
immunohistochemical studies and lack of appropriate validation controls in many reports. 
The standing question is whether those changes in expression have any causal relationship 
with disease progression. An additional complication is that, in an era when microarray 
mRNA databases are routinely used, there are significant discrepancies between the 
available information on PKC expression at the mRNA and protein levels. This can be 
epitomized for PKCε, an isozyme that is markedly up-regulated in most epithelial cancers at 
the protein level [4–7], but shows only marginal or no changes in mRNA databases (Fig. 2). 
Whereas high expression of PKCε in tumors may involve changes at a transcriptional level, 
expression underestimation by databases may relate to post-translational events that 
ultimately modify protein stability. Modeling expression patterns from mRNA expression 
databases, which in most cases have not been generated from microdissected tissues, can 
distort the actual profile of PKC protein expression in tumors and ultimately mislead our 
efforts to correlate those changes with clinicopathological outcomes.
Another important issue that received little attention is the activation status of PKC 
isozymes in cancer. There is little experimental evidence supporting either hyperactivation 
or hypoactivation of PKCs in human tumors. Unlike other important kinases implicated in 
cancer progression, such as Erk, JNK, or Akt, phosphorylation of PKCs does not necessarily 
correlate with activation status. One impediment to address this important matter is the lack 
of reliable readouts associated with the activated status of individual PKCs, in particular 
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PKC isozyme-specific substrates that could be detected in human tumors. Genetically 
encoded reporters for PKC isozymes reliably detect enzyme activation and substrate 
phosphorylation in cellular models in culture [8–12]; however, we still lack tools to detect 
activated PKCs or their specific substrates in tumors by immunohistochemistry. The 
association of PKCs to membranes is a requisite for the activation of DAG/phorbol ester-
regulated PKCs [3]. Whereas some exceptions have been reported, such as the activation by 
proteolytic cleavage [13], cPKCs and nPKCs translocate to the plasma membrane in 
response to stimuli such as growth factor receptor activation. Although less understood at a 
mechanistic level, cPKCs and nPKCs can also redistribute to a number of intracellular 
compartments, including the translocation to mitochondria, Golgi, endoplasmic reticulum 
and nuclear membrane. Constitutive association of PKCs to internal membranes has also 
been reported [14–17]. At present, we do not understand well the significance of such 
compartmentalization and whether PKCs are fully activated in discrete intracellular 
locations due to differential membrane compositions, DAG availability, and/or the presence 
of isozyme-specific protein partners that cooperate for the transition to an activated status. 
All these factors conspire against a full appreciation on how PKC activation contributes to 
disease progression.
PKCα: tumor promoter or tumor suppressor?
PKCα has been long recognized as a regulator of multiple aspects of tumor growth, 
including proliferation, survival, differentiation and motility. As several studies linked 
PKCα to enhanced proliferation and anti-apoptotic signals [18–22], there has been 
significant interest in this kinase as a potential target for cancer therapy. However, PKCα 
had limited success as a drug target for cancer. Indeed, due to its very complex and highly 
tissue-specific functions, PKCα acts as a tumor promoter or a tumor suppressor depending 
on the context. To add another level of complexity, PKCα is up-regulated in some cancers 
(such as bladder, endometrial, and breast cancer) and down-regulated in others (such as 
colorectal tumors and malignant renal cell carcinomas [23–24]). There is little information 
on substrates specifically phosphorylated by PKCα or genetic programs controlled by 
PKCα, thus rendering our comprehension of the molecular basis of this functional diversity 
incomplete.
Early studies in glioma cellular models established that PKCα is up-regulated relative to 
astrocytes. Antisense oligonucleotides against PKCα inhibit the proliferation of glioma cells 
[25]. Consistent with these results, overexpression of PKCα in U87 glioblastoma cells 
enhances proliferation. Although overexpression of PKCα did not protect U87 cells from 
apoptosis by etoposide, other studies documented that PKCα renders enhanced resistance to 
apoptosis in response to radiation and chemotherapy [18, 26–27]. In U1242 glioblastoma 
cells, PKCα regulates the activation of NF-κB, which results in a pro-survival phenotype 
[28]. Aprinocarsen (Ly900003, ISIS 3521), an antisense oligonucleotide directed against the 
3′-untranslated region of PKCα, arrests A172 glioma cells and induces p53. Aprinocarsen 
also impairs tumor growth in xenograft models. In combination with other chemotherapeutic 
agents, aprinocarsen was shown to have additive or super-additive antitumor effects [29–
31]. Despite encouraging responses in early clinical trials, this anti-PKCα agent failed to 
make it into phase III clinical trials either alone or in combination with other agents [29]. 
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Another PKCα inhibitor, the staurosporine analogue UCN-01 [32] proved to be a potent 
anti-tumor agent in preclinical models, but its effect cannot be explained simply by PKCα 
inhibition [33]. It is also intriguing that PKCα RNAi depletion but not PKCα inhibition 
impairs the growth of glioma cell lines, suggesting that the effect is independent of the 
catalytic phosphotransferase activity of the enzyme [34].
Another interesting link between PKCα and cancer progression has been established in 
breast. Ways et al. showed that ectopic overexpression PKCα in MCF-7 breast cancer cells 
(which express low levels of PKCα) enhances proliferative rate, confers anchorage-
independent growth and tumorigenic potential in nude mice, and drastically alters cell shape 
by inducing loss of an epithelioid morphology. PKCα overexpressing MCF-7 cells have 
reduced estrogen receptor (ER) levels, suggesting that PKCα contributes to the switch from 
ER-positive to ER-negative status [35]. Likewise, Tonetti et al. found that stable 
overexpression of PKCα in T47-D breast cancer cells is accompanied by down-regulation of 
ER function [36] and confers hormone-independent tumor growth that cannot be inhibited 
by tamoxifen [37]. A recent study suggests that this effect may be mediated by Notch-4 [38]. 
Elevated PKCα expression was suggested to be a predictor of tamoxifen treatment failure, 
which fits with the observation that patient tumor samples with elevated PKCα levels are 
generally negative for estrogen receptor (ER) expression, and these patients respond less to 
endocrine therapy [39–40]. A recent study by Larsson and coworkers demonstrated that 
PKCα levels correlates with estrogen receptor (ER) and progesterone receptor negativity, 
proliferative activity, and tumor grade [41]. Thus, altogether it seems that PKCα is a 
biomarker for poor prognosis and endocrine therapy resistance in breast cancer. PKCα is 
also an effector of ErbB2 in breast cancer cells, and ErbB2 siRNA depletion decreases 
PKCα protein levels. Moreover, ErbB2 overexpression correlates with membrane-associated 
staining of PKCα in human breast cancer specimens, suggesting that ErbB2 drives the 
constitutive activation of PKCα [42]. Gö6976, a pharmacological inhibitor of cPKCs [43], 
abrogates ErbB2-mediated up-regulation of urokinase-type plasminogen activator (uPA) and 
cell invasion [44]. Whereas PKCα expression is higher in triple-negative breast cancers than 
to other subtypes [45], we still need to underscore meaningful associations of this PKC with 
genetic alterations specific for each breast cancer subtype.
In a very recent study by the Weinberg laboratory, PKCα was found to be enriched in 
epithelial-to-mesenchymal (EMT)-induced mammary cells [46]. Interestingly, inhibitors 
targeting PKCα preferentially kill mesenchymal cells relative to epithelial cell lines, and 
likewise, depletion of PKCα using shRNA results in a substantial loss of mesenchymal cells. 
A PKCα signaling network is activated preferentially in cancer stem cells by PDGF and 
involves the transcription factor FRA1. The activation of the PDGFR-PKCα-FRA1 pathway 
in breast cancer stem cells makes them particularly susceptible to pharmacological inhibition 
of PKCα. Whereas the relevance of this pathway has to be established in other cancer types, 
this study certainly shed light into the potential therapeutic value of targeting PKCα in 
epithelial cancers.
Despite the reported pro-tumorigenic effects of PKCα, it has been also described as a 
growth inhibitory kinase in several cell types. For example, activation of PKCα in non-small 
cell lung cancer (NSCLC) cells leads to p21Cip1 up-regulation, inhibition of cell growth and 
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senescence [47]. Not surprisingly, aprinocarsen showed no significant benefit for NSCLC 
patients, either alone or in combination with other chemotherapeutic agents [29].
Years ago, Black and coworkers reported that PKCα activation triggers a program of cell 
cycle exit-specific events in intestinal crypts through the repression of cyclin D1 translation 
[48–49]. This effect implicates the activation of the translational repressor 4E-BP1 through a 
phosphatase 2A-dependent mechanism and in a PI3K/Akt-independent manner [50]. PKCα 
also inhibits the Wnt/β-catenin pathway in colon cancer cells and represses the expression of 
β-catenin target genes such as c-Myc [51], a mechanism that may involve receptor-related 
orphan receptor alpha RORα [52]. Interestingly, a small molecule screening identified a 
compound (CGK062) that promotes PKCα-mediated phosphorylation of β-catenin, leading 
to its proteasomal degradation. This compound has anti-tumor effects in nude mice [53]. The 
expression of PKCα in proliferating intestinal epithelial cells is repressed both in vitro and 
in vivo by the SOX9 transcription factor [54]. All neoplasm arising in APC−/+ mice, which 
develop multiple intestinal neoplasia, express low levels of PKCα. Remarkably, loss of 
PKCα directly correlates with aggressiveness of intestinal tumors. Furthermore, tumor 
formation and aggressiveness are enhanced in double transgenic APCMin/+; PKCα−/− mice 
(Fig. 3A). Interestingly, spontaneous intestinal tumors develop in PKCα−/− mice [55–56]. 
PKCα also suppresses skin tumor formation induced by DMBA. However, PKCα 
deficiency does not alter the size or malignancy of skin tumors [57].
PKCα activation by phorbol esters contributes to cell death in androgen-dependent prostate 
cancer cells. Activation of PKCα in LNCaP cells leads to a rapid and reversible 
dephosphorylation of Akt possibly via activation of a PP2A phosphatase [58]. Stable DAG 
analogues with preferred selectivity for PKCα also induce apoptosis in LNCaP cells [59]. A 
kinase-dead PKCα mutant blocks the apoptotic response elicited by a combination of PMA 
treatment and radiation, and a constitutively active PKCα mutant sensitizes cells to radiation 
treatment. While radiation alone reduces initial LNCaP tumor growth and serum PSA levels 
in mice, combinatorial treatment with PMA or a specific PKCα DAG activator eliminates 
tumor growth and drastically reduces PSA levels [60].
A very interesting recent study by the group of Alan Fields reported that PKCα plays a key 
role in K-Ras-mediated lung tumorigenesis [61]. There is an evident loss of expression of 
PKCα in primary human NSCLC tumors. Remarkably, PKCα knockout mice display 
enhanced K-Ras lung tumorigenesis (Fig. 3B) and bypass oncogene-induced senescence. 
The tumor promoting effect caused by loss of PKCα may involve the expansion of 
bronchoalveolar stem cells (BASCs). Mechanistic analysis determined that loss of PKCα 
reduces the activation of p38 MAPK in BASCs from K-Ras tumors and augments TGFβ1 
mRNA levels. Moreover, a TGFβ receptor inhibitor reversed the effect of PKCα loss in K-
Ras/PKCα-depleted tumors. This study reported the inhibitors of DNA binding (Id) Id1-3 as 
potential downstream targets of PKCα-dependent tumor suppressor activity, as also 
observed in other intestinal cells and fibroblasts [62–63]. Therefore, PKCα suppresses tumor 
initiation and progression in the K-Ras lung cancer mouse model through a p38 MAPK/
TGFβ signaling axis.
Garg et al. Page 5
Oncogene. Author manuscript; available in PMC 2015 May 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
PKCα has been implicated in invasion and metastasis, mostly as a positive regulator [64–
69]. In breast cancer cells, ErbB2-dependent activation of PKCα promotes cell invasion 
[42]. PKCα overexpressing MCF-7 breast cancer cells display enhanced motility, which was 
attributed to decreased expression of E-cadherin and β-catenin, and high expression of 
MMP-2/MMP-9 [70–71]. A specific PKCα peptide inhibitor significantly reduced 
metastasis of mouse mammary cancer cells to the lungs. Analysis of highly metastatic (4T1) 
and non-metastatic (JC) mouse mammary cells indicates that the basal activation of PKCα is 
higher in the former. Treatment with this PKCα antagonistic peptide did not affect tumor 
growth but blocked metastasis of 4T1 cells to the lungs. PKCα inhibition blocks metastasis 
by inhibiting the activation of MMPs in combination with decreased NF-κB activity and 
CXCL12 receptor levels [72].
PKCβ isozymes: spliced variants with distinct involvement in cancer
PKCβI and PKCβII, spliced variants encoded by the PRKCB gene have differential tissue 
expression and a distinct involvement in cancer. PKCβ isoforms have been implicated in the 
progression of many cancer types, including lymphoma, glioblastoma, breast, prostate, and 
colorectal cancers [73–77]. It is not fully understood why PKCβ isoforms have in some 
cases different functions. This may relate to unique lipid- and protein-interactions via their 
different C-terminal domains that confer distinctive localization properties [78–80]. 
However, many studies using pharmacological agents do not distinguish between PKCβ 
subtypes.
Early studies reported elevated PKCβII levels both during the initial stages of tumorigenesis 
and in colonic carcinomas relative to normal colonic tissue [81–83]. Spindler et al. reported 
that 18% of primary adenocarcinomas exhibit very high levels of PKCβII, which correlates 
with poor survival rates [84]. PKCβII has been implicated in colon cancer cell proliferation 
in vitro [85–86]. Murray et al. generated a transgenic mouse model overexpressing PKCβII 
in the intestinal epithelium. In addition to epithelial hyperproliferation, these mice display 
increased susceptibility to carcinogen-induced preneoplastic lesions in the colon [87]. The 
phenotype has been linked to repression of TGFβ signaling and elevated COX-2 expression 
[73]. In the proximal colon, activated K-Ras induces the expression of PKCβII, activation of 
the Mek/Erk signaling axis, and increased epithelial cell proliferation [88]. In a cellular 
model of intestinal cells, stable overexpression of PKCβII confers an invasive phenotype 
mediated by a Ras/Mek/PKCι/Rac1-dependent pathway [89]. The role of PKCβI in the 
colon is less clear. Overexpression of PKCβI suppresses the growth of HT29 and SW480 
colon cancer cell xenograft [90]. However, other report shows that expression of PKCβI 
confers resistance to apoptosis by TNFα and paclitaxel [91].
PKCβI expression positively correlates with high Gleason scores in prostate carcinomas, and 
inhibition of this kinase blocks androgen receptor-induced tumor cell proliferation in vitro 
and xenograft growth in vivo. Notably, PKCβI phosphorylates histone H3 and inhibits 
androgen-dependent transcription [92]. A study using a specific PKCβII peptide inhibitor 
showed that this isoform is involved in prostate cancer cell proliferation. PKCβII also plays 
an important role in endothelial cell proliferation, and inhibition of PKCβII reduces 
angiogenesis. These effects were linked to dysregulation of cytokinesis and microtubule 
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organization [74]. Enzastaurin, an inhibitor with some degree of specificity towards PKCβ, 
displays antiproliferative effects in PC3 cells [93].
Overexpression of either PKCβI or PKCβII in MCF-7 breast cancer cells promotes cell 
growth and enhances cyclin D1 levels, whereas dominant-negative PKCβ mutants inhibit 
growth [94]. On the other hand, another report showed that PKCβI overexpression induces a 
less aggressive biological behavior in MCF-7 cells characterized by reduced tumor 
formation [95]. In a murine mammary model, PKCβI inhibits tumorigenesis despite having a 
positive effect on growth in culture. Moreover, tumor cells that overexpress PKCβI have 
attenuated metastatic capacity to the lungs [96]. Enzastaurin has significant effects on the 
growth of breast cancer cells in vitro and in vivo [97–98]. High levels of PKCβII have been 
reported in several breast cancer cell lines and patient samples. The levels of cytoplasmic 
PKCβII expression positively correlate with ErbB2/Her2 levels, while nuclear PKCβII 
positively correlates with ER levels [99].
PKCβII is expressed in human NSCLC specimens with significant variability, both in tumor 
cells and the stroma [100]. Enzastaurin in combination with the antifolate pemetrexed causes 
G2/M checkpoint abrogation and apoptosis in lung cancer cells [101]. In cell culture, 
enzastaurin is a potent inhibitor of VEGF-stimulated proliferation of endothelial cells, and in 
vivo this inhibitor causes a significant reduction in intratumoral vessels that parallels a delay 
in lung cancer tumor growth [100]. Enzastaurin also enhances the anti-angiogenic effects of 
radiation in NSCLC models [102]. The PKCβ inhibitor, Enzastaurin, regulates proliferation 
of glioblastoma cells by supporting the activity of GSK3, S6 kinase and Akt [103]. The 
effect of the PKCβ inhibitor was also shown in U87MG human glioblastoma cells 
inoculated into nude mice. Enzastaurin proved to be efficient as an anti-angiogenic 
compound in models of glioblastoma [77], however clinical trials in patients with recurrent 
high-grade glioma show limited success when this inhibitor was used as a monotherapy 
[104].
Patients with diffuse large B-cell lymphoma that express PKCβ have reduced overall 
survival compared to those that are negative for this kinase [105–106]. Enzastaurin displays 
pro-apoptotic properties in T-cell and B-cell lymphoma cell lines [107–108]. There is 
significant interest in using this PKCβ inhibitor for the treatment of various types of 
lymphomas, both as a single agent and in combination therapies [109–110]. Taking 
advantage of a PKCβ knockout mouse model, it has been recently demonstrated that stromal 
PKCβII is indispensable for the survival of chronic lymphocytic leukemia (CLL) B cells. 
The fact that stromal PKCβII is up-regulated in biopsies from patients with CLL, and that 
CLL cells induce the expression of stromal PKCβ [111], highlights the need to better 
understand how this PKC contributes to cancer development in the context of the different 
tumor microenvironments.
PKCδ: complex roles in apoptosis, tumor growth and metastasis
PKCδ has been widely characterized as a pro-apoptotic and anti-proliferative kinase. In 
addition, PKCδ has been broadly implicated as a death mediator of chemotherapeutic agents 
and radiotherapy [112–115]. PKCδ is involved both in DNA damage and receptor-mediated 
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cell death [3, 115–116]. Initial work from the Reyland lab showed that PKCδ is cleaved by 
caspase-3 and mobilizes from the cytoplasm to the nucleus after treatment with genotoxic 
agents [13]. Other studies showed that PKCδ-mediated apoptosis involves the allosteric 
activation of the enzyme rather than proteolytic cleavage. For example, in androgen-
dependent prostate cancer cells, PKCδ activation triggers an apoptotic response without the 
generation of a constitutively active catalytic fragment [117]. This effect involves the 
activation of the p38 MAPK cascade [118] and is mediated by a RhoA/ROCK/p21Cip1-
dependent pathway [119]. PKCδ-mediated apoptosis in androgen-dependent prostate cancer 
cells occurs through the autocrine secretion of TNFα and TRAIL, which induce caspase-8 
cleavage through the JNK and p38 MAPK cascades [120–122]. The discrepancies in the 
mechanisms of PKCδ activation among the various studies may be explained by cell type 
differences and nature of the stimulus.
An inhibitory role for PKCδ in proliferation has been reported in a number of cellular 
models. The initial observations by Mischak et al. that ectopic overexpression of PKCδ 
confers growth inhibitory properties to NIH 3T3 cells [123], were later recapitulated in 
many other cell lines. Depending on the cell type, activation of PKCδ can induce cell cycle 
arrest either in G1 or G2 [49, 124]. Our laboratory showed that treatment of lung cancer 
cells with phorbol esters induces cell cycle arrest in G1 through the induction of p21cip1 and 
Rb dephosphorylation [125]. However, it has been also noted that ectopic expression of 
PKCδ stimulates quiescent cells to initiate G1 phase cell cycle progression. Notably, PKCδ 
overexpressing cells arrest in S phase rather than completing the cell cycle [126].
It is important to mention that studies ascribed pro-survival properties to PKCδ in a number 
of tumor models, including breast, lung, pancreatic, and liver cancer [116]. Moreover, 
ectopic expression of PKCδ in mammary cells confers anchorage-independent growth 
properties and enhances the resistance to apoptotic stimuli [127]. The scenario that PKCδ 
could be a tumor promoting kinase rather than a tumor suppressor began to shape new 
paradigms in PKC isozyme function, and clearly points to an exquisite cell type selectivity.
Data from patients cannot point to a clear link between PKCδ expression levels and clinical 
outcome. Loss of PKCδ expression has been reported in a few cancer types [128–130], but 
this down-regulation could not be unambiguously linked to tumorigenesis. PKCδ is up-
regulated in some cancer types [131–132]. PKCδ is barely detected in normal prostate 
epithelial cells, however high PKCδ expression could be observed in prostate pre-neoplastic 
lesions and carcinomas [133–134]. In breast cancer specimens, PKCδ mRNA levels are 
significantly higher in ER-positive tumors and a positive correlation between high PKCδ 
mRNA levels and reduced overall survival has been reported [135]. Interestingly, the 
expression of PKCθ, an isozyme related to PKCδ, is dysregulated in some cancers [132, 
136–138].
Emerging studies using genetically engineered mice began to shed light into the 
involvement of PKCδ in tumorigenesis. PKCδ skin transgenic mice are resistant to tumor 
promotion by DMBA/PMA [139]. Studies using PKCδ knockout mice revealed contrasting 
effects particularly in the context of specific genetic alterations. Reyland and coworkers 
investigated the involvement of PKCδ in K-Ras-dependent tumorigenesis and found that the 
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incidence of urethane-induced lung tumors (which display activating mutations in K-Ras) is 
reduced in a PKCδ-null background. Moreover, PKCδ RNAi depletion inhibits anchorage-
independent growth, invasion, migration, and tumorigenesis in K-Ras-dependent NSCLC 
cells [140]. The Reyland lab also described a positive role for PKCδ in mammary 
tumorigenesis in the context of ErbB2 overexpression. A meta-analysis of ErbB2-positive 
breast cancers shows increased PKCδ expression and a negative correlation between PKCδ 
expression and prognosis. Most remarkably, there is a significant delay in tumor onset in 
MMTV-ErbB2(Neu) in a PKCδ-null background [141]. A tumorigenic role for PKCδ has 
been also reported in a model of pancreatic cancer. Indeed, overexpression of PKCδ (as 
observed in human ductal carcinomas) leads to increased anchorage-independent growth and 
tumorigenesis in vivo [142]. Also, in a PC-3 xenograft model, PKCδ activation promotes 
tumor growth and increases angiogenesis through a mechanism that involves ROS, NADPH, 
and HIF-1α [143].
PKCδ generally has a positive role in migration and invasiveness [144–147]. In prostate 
cancer cellular models PKCδ has been implicated in invasiveness and the control of collagen 
secretion induced by overexpression of the oncoprotein PCPH [134]. Breast cancer models 
provided controversial evidence for the involvement of PKCδ in invasion. Whereas a study 
showed that PKCδ overexpression in highly motile BT-549 breast cancer cells reduces 
migration and PKCδ down-regulation enhances motility and MMP-9 secretion in MCF-7 
cells [148], other study reported that enhanced migration induced by forced EGFR 
overexpression in MCF-7 cells requires PKCδ [149]. PKCδ was found to inhibit the 
production of proteolytic enzymes in murine mammary cells, possibly limiting metastatic 
dissemination[127]. Down-regulation of PKCδ suppresses lung colonization in the murine 
mammary breast cancer model MTLn3 without affecting the growth of primary tumor [150]. 
Studies performed in BL6 murine melanoma cells showed that PKCδ overexpression 
increases their metastatic capacity in vivo, possibly due to an increase in the plasma levels of 
TGFβ1 [151–152]. A similar pro-metastatic effect of PKCδ has been shown in the human 
pancreatic cell line PANC1 [142].
The multiplicity of effects regulated by PKCδ and the complexity of the effects in cell cycle 
regulation, cell motility, tumorigenicity and metastasis, both in positive and negative 
manners (Fig. 4), would argue that this kinase is not a likely candidate for the therapy of 
cancer.
PKCε: an oncogenic and metastatic kinase
PKCε has been originally described as an oncogenic kinase [123, 153–154], and is known to 
signal via the Ras-Raf-1 signaling pathway [155–158] as well as other pathways. PKCε-
transformed fibroblasts secrete increased amounts of TGF-β and possibly other mitogens, an 
indication that growth autocrine loops may account for its oncogenic activity [159–160]. 
PKCε is overexpressed in a large number of cancers. For example, PKCε is overexpressed in 
~75% of primary tumors from invasive ductal breast cancer patients [7]. Increased PKCε 
staining correlates with high histologic grade, positive ErbB2/Her2 status, and negative 
estrogen and progesterone receptor status [7]. Overexpression of PKCε has been reported in 
the majority (>90%) of primary NSCLC cancers relative to normal lung epithelium [5]. 
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PKCε levels are elevated in prostate cancer relative to benign prostatic epithelia [161], and a 
correlation with aggressiveness of human prostate cancer has been found [4]. PKCη, an 
isoform related to PKCε, has also been shown to be up-regulated in some cancers [162–163] 
but down-regulated in others [164].
Not surprisingly, studies from several laboratories highlight a role for PKCε in cell cycle 
control, specifically in G1 to S progression [165–167]. In addition, PKCε promotes survival 
in many cell types [6, 168–170]. The survival activity of PKCε involves the modulation of 
caspases and Bcl-2 family members [168, 171–173]. Forced expression of PKCε in LNCaP 
prostate cancer cells confers resistance to PMA-induce apoptosis by preventing Bax 
oligomerization; moreover, it leads to accelerated proliferation of LNCaP cells due to 
constitutive activation of the Erk cascade [169]. Our laboratory recently demonstrated that 
PKCε modulates Bad phosphorylation at Ser112 to protect LNCaP prostate cancer cells 
against apoptosis induced by PMA or TNFα [172]. PKCε protects glioma and lung cancer 
cells from TRAIL-induced apoptosis [170, 174–175]. Subsequent studies by Basu and 
coworkers revealed that PKCε inhibits cell death in breast cancer cells, partly by preventing 
activation and translocation of Bax to the mitochondria [176]. PKCε inhibition/depletion 
impairs proliferation and anchorage-independent growth of human NSCLC cells [5, 177]. 
Many pro-apoptotic genes up-regulated upon PKCε RNAi depletion in lung cancer cells are 
also down-regulated in human lung adenocarcinomas [177]. RWPE-1 cells, a model of 
normal immortalized prostate epithelial cells, express very low levels of PKCε as compared 
to different human prostate cancer lines, and ectopic expression of PKCε in RWPE-1 cells 
confers growth advantage and leads to Erk and Akt activation [6]. Recently, our laboratory 
identified a key role for PKCε as a mediator of NF-κB signaling in prostate cancer [178]. 
PKCε inhibition/depletion impairs constitutive and TNFα-dependent activation of NF-κB as 
well as the induction of NF-κB responsive genes pertaining to cell survival, proliferation, 
metastasis and invasion, such as COX-2, MMP-9, VEGF, and IL-6 [178].
Overexpression of PKCε in androgen-dependent LNCaP cells initiates tumor growth in vivo 
both in intact and castrated athymic nude mice [179], thereby indicating that PKCε has the 
potential to advance the progression of prostate cancer and initiate recurrent tumor growth in 
the absence of androgens. In concordance, another study found that PKCε overexpression in 
breast cancer cells causes tumor growth in BALB/c mice with significant increase in the 
incidence and number of spontaneous experimental lung metastases [96]. In line with these 
results, depletion of PKCε from lung cancer cells using shRNA markedly inhibited 
xenograft growth in nude mice. Furthermore, the PKCε peptide translocation inhibitor 
εV1-2 blocks NSCLC tumor growth in nude mice. Moreover, both shRNA depletion and 
pharmacological inhibition of PKCε causes a strong induction of cell death in xenograft 
tumors [177].
Unfortunately, there has been little work intending to recapitulate PKCε overexpression as 
observed in human cancer. Our laboratory developed prostate-specific transgenic mice that 
overexpress PKCε in the normal prostate in vivo under the control of the androgen-
responsive probasin (PB) promoter, which leads to the formation of preneoplastic lesions 
(Fig. 5). Conversely, similar mouse models for other PKCs (PB-PKCα and PB-PKCδ mice) 
do not display any noticeable phenotypic changes in the prostate. Furthermore, elevated 
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phospho-Akt as well as hyperactivation of Akt effectors S6 and mTOR could be detected in 
hyperplasia and PIN lesions from PB-PKCε transgenic mice. Besides, PKCε overexpression 
confers resistance to apoptosis induced by androgen ablation, highlighting a pro-survival 
role of PKCε in the mouse prostate [6]. Hyperactivation of NF-κB and Stat-3 were evident 
in the PIN lesions of PB-PKCε transgenic mice relative to the normal areas or regions with 
mild hyperplasia [6, 178].
Prostates of TRAMP mice (a model that spontaneously develops progressive invasive 
prostate cancer) have very high PKCε protein levels compared to prostates of control mice 
[4]. A recent study demonstrated that genetic ablation of PKCε in TRAMP mice inhibits 
prostate cancer development and metastasis [180]. Deletion of PKCε in TRAMP mice 
decreases the phosphorylation/activation of Stat3 as well as its nuclear translocation and 
DNA-binding activity. It has been proposed that loss of PKCε in TRAMP transgenic mice 
reduces the expression of proliferation, survival and metastasis markers, including COX-2, 
Bcl-xL, cyclin D1 and VEGF, as well as it decreases serum IL-6 levels.
A growing body of evidence indicates that PKCε is implicated in tumor cell invasion and 
metastasis. Enhanced PKCε levels are associated with invasion and/or metastasis of human 
breast, glioma and renal cell carcinoma [7, 166, 181]. PKCε contains an actin-binding motif 
that positions this kinase within a cytoskeletal matrix where many PKC substrates are 
localized [182–185]. Deletion of this motif abrogates invasion and metastatic spread of 
tumors driven by PKCε overexpression [186]. In human glioma cells, the PKC-interacting 
protein RACK1 appears to link activated PKCε to the integrin β chain at focal adhesions, 
and PKCε mediates the adhesion and motility of cells via Erk phosphorylation [187]. PKCε 
also promotes the assembly of matrix adhesions containing actin filaments and β1-integrins, 
and integrin signaling links PKCε to the Akt survival pathway in recurrent prostate cancer 
cells [188]. In models of breast and head and neck cancer, PKCε regulates motility and 
invasion, at least in part due to the activation of small Rho GTPases, specifically RhoA 
and/or RhoC [7, 189]. Very recent work from our laboratory showed that targeted disruption 
of PKCε in lung cancer cells reduces motility through Rac1 inactivation. Several 
extracellular matrix proteases are down-regulated in PKCε-depleted lung cancer cells [190]. 
Consistent with a role for PKCε in metastatic dissemination, PKCε-depleted NSCLC cells 
fail to colonize lungs after tail vein injection in mice [190]. Likewise, a study from the 
Urtreger’s laboratory showed that inoculation of PKCε overexpressing breast cancer cells in 
mice enhances the incidence and number of spontaneous and experimental lung metastases 
[96].
Verma and coworkers generated skin transgenic mice expressing PKCε under the control of 
the human K14 promoter, which exhibit phenotypic abnormalities including inflammation, 
hyperkeratosis, hyperplasia, cellular hypertrophy and ulceration. Highly malignant and 
metastatic squamous cell carcinomas develop in the skin of PKCε transgenic mice [191–
192]. Additionally, PKCε overexpression has been shown to sensitize the mouse skin to 
UVR-induced carcinogenesis [193]. A subsequent study demonstrated that skin transgenic 
PKCε mice develop a myeloproliferative-like disease [194].
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Altogether, these observations establish that PKCε overexpression is linked to an aggressive 
phenotype and suggest that targeting PKCε could be an effective anticancer strategy. 
Whereas the development of PKCε inhibitors targeting the ATP-binding site may be 
challenging due to the high homology of this site among PKCs, agents directed against 
domains implicated in translocation may be valuable. In that regard, the PKCε translocation 
inhibitor εV1-2 has anti-tumorigenic activity in NSCLC cells [177], and a bifunctional 
peptide in which εV1-2 has been linked to the 12-mer cancer homing peptide HN1 impairs 
the growth of head and neck squamous cell carcinoma cells in xenografts [195]. Lastly, Ras-
driven and EMT-dependent phenotypes in breast cancer cells could be reversed by 
PF-526355, an ATP mimetic inhibitor with selectivity for PKCε and PKCθ. This inhibitor 
impairs the growth of MDA-MB-231 breast cancer xenografts in mice, thus representing a 
promising agent for cancer therapy [196].
Atypical PKCs ζ and ι: opposite roles in cancer
aPKC isozymes, which comprise PKCζ and PKCι (PKCλ), are structurally and functionally 
distinct from other PKCs in that they have a single DAG/phorbol ester unresponsive C1 
domain and lack a C2 domain [197–198]. Regardless of controversies in the literature 
largely due to the use of non-specific approaches such as inhibitory peptides and dominant-
negative mutants, many studies point to a tumor suppressor function of PKCζ, whereas 
PKCι essentially fulfills the criteria of an oncogenic kinase (Fig. 6).
Both up- and down-regulation of PKCζ has been shown in human cancer. PKCζ up-
regulation has been reported in prostate cancer, bladder cancer, and lymphomas [199–204], 
whereas down-regulated expression of PKCζ has been shown in glioblastoma, lung cancer, 
kidney, renal clear cell carcinoma, melanoma, and pancreatic cancer [205–214]. A pro-
apoptotic function for PKCζ has been described in several cancer models. For example, 
PKCζ inhibits growth and promotes differentiation and apoptosis in colon cancer cells. The 
inhibitory effect of PKCζ on the transformed phenotype of these cells suggests that down-
regulation of PKCζ may contribute to colon tumorigenesis [215]. PKCζ also exhibits a pro-
apoptotic function in ovarian cancer [216]. In murine TRAMP prostate cancer cells, 
expression of a constitutively activated PKCζ mutant enhances proliferation, whereas PKCζ 
inhibition leads to Akt activation and enhanced cell survival [217]. There are several reports, 
however, highlighting a pro-survival role for PKCζ [218–222].
PKCζ-deficient mice display increased Ras-induced lung carcinogenesis, arguing for a role 
for this aPKC as a tumor suppressor in vivo. It has been postulated that the tumor suppressor 
activity of PKCζ occurs through its ability to down-regulate Ras-induced IL-6 production. 
The enhanced secretion of IL-6 in PKCζ-deficient Ras-transformed cells is essential for 
growth under conditions of limited nutrients and mitogens [211]. Genetic inactivation of 
PKCζ in mice in a Pten-deficient background leads to invasive prostate carcinoma. A 
significant correlation between PKCζ and Pten levels exists in human prostate tumors, and 
PKCζ is significantly reduced in metastatic vs. primary tumors with low Pten. Analysis of 
gene signatures in PKCζ-deficient cells revealed a link with c-Myc. Indeed, c-Myc is a 
contributor to the more aggressive phenotype associated with PKCζ loss [223]. Loss of 
PKCζ also allows glucose-addicted human cancer cells to reprogram their metabolism in 
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response to glucose deprivation by augmenting the utilization of glutamine through the 
serine biosynthetic pathway [224].
Accumulating evidence established that PKCι is an oncogenic kinase and that it contributes 
to the transformed phenotype. Overexpression of PKCι is observed in many human cancers, 
including colon, lung, pancreas, breast, prostate and ovarian cancer. The PKCι gene 
(PRKCI) is amplified in some human cancers [225–227], although PKCι overexpression is 
not always associated with gene amplification [228–230]. This has been well summarized in 
a review by Murray et al [231].
PKCι expression is elevated in NSCLC tumors and cell lines, and is required for the 
transformed phenotype of NSCLC cells harboring oncogenic K-Ras mutation [232–235]. 
NSCLC cell lines without Ras mutation also depend on PKCι for their malignant phenotype 
if they harbor PRKCI gene amplification [235]. PKCι mediates its effects through a Rac1-
Pak-Mek-Erk dependent mechanism [89]. By means of a proteomics approach, Justilien et 
al [236] identified the Rho-GEF Ect2 as a component of the PKCι-Par6 complex that is 
required for transformed growth. The Ect2 gene co-amplifies with PRKCI suggesting a 
coordinated mechanism for tumorigenesis. Disruption of the PKCι-Par6 interaction, as 
caused with the anti-rheumatic agent aurothiomalate (ATM), potently inhibits growth of 
PKCι-overexpressing cell lines. ATM inhibits K-Ras-mediated expansion of 
bronchoalveolar stem cells and lung tumor growth in vivo [233, 237]. On the other hand, 
aPKCs appear to be dispensable for mammalian hematopoietic stem cell function [238]. 
PKCι has been also implicated in colon and pancreatic cancer using cell lines and animal 
models [229–230]. PKCι is required for hedgehog signaling in basal cell carcinomas. 
Indeed, PKCι functions downstream of smoothened (SMO) to phosphorylate and activate 
the GLI1 transcription factor. Moreover, PKCι is up-regulated in tumors resistant to SMO 
inhibitors, and targeting PKCι suppresses the growth of resistant basal carcinoma cell lines 
[239]. Other interesting signaling connections have been established for PKCι, including 
mutually antagonistic regulation with RhoB in glioblastoma cell invasion [240], links with 
the NF-κB pathway [241–242], as well as association with cell cycle proteins cyclin E in 
ovarian cancer [226] and S-phase kinase-associated protein 2 (SKP2) in esophageal cancer 
[243].
Final remarks
Tangible progress has been made in the last 30 years in understanding the regulation and 
cellular functions of PKC isozymes in cancer. The picture that emerged, however, is less 
than clear. What we have learned over the last years is that the biology of PKC isozymes is 
exceptionally complex, and that many studies in cell lines do not necessarily apply to in vivo 
models. For the next wave of studies on PKC function, the generation of animal models 
recapitulating the scenarios observed in different cancer types should be a priority. 
However, it is still not known whether the activation status of different members of the PKC 
family is altered in cancer and whether activated PKCs functionally interact with oncogenes 
and tumor suppressors genes driving the tumorigenic and metastatic phenotype.
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One would expect that PKC is a promising target for cancer therapy, but only for specific 
PKC isozymes that display oncogenic activity, such as PKCε and PKCι. The portfolio of 
available PKC inhibitors remains narrow, and unfortunately the majority of compounds lack 
specificity among members of the PKC family or even with other kinases unrelated to PKC. 
Hence, there is a great need to design selective small molecule inhibitors for PKC isozymes 
that have sufficient potency to impair PKC function in vivo. There may be concrete 
opportunities to rationally design inhibitors against the ATP-binding site, but this is still 
challenging due to the high homology among PKCs in that region. Some examples of small 
molecules capable of disrupting protein-protein interactions for PKC isozymes provided 
proof-of-principle for alternative approaches in the design of PKC modulators [177, 237, 
244]. C1 domain ligands, such as the bryostatins [245–246], did not show major beneficial 
effects in patients despite their anti-tumor effects in mice [244]. One may envision that PKC 
isozyme specific inhibitors may possibly work in combined therapies with chemotherapeutic 
agents for discrete cancer types. Translating PKC modulators into a clinical setting remains 
a formidable challenge that we face for the next years.
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Figure 1. 
Structure of PKC isozymes. PKCs are multidomain proteins that are regulated by lipids and 
protein-protein interactions. Diacyclycerol (DAG) generated upon activation of receptors 
causes the activation of cPKCs and nPKCs, and its actions are mimicked by phorbol esters. 
aPKCs do not respond to DAG or phorbol esters. PKCs activate a number of signal 
transduction pathways that regulate tumorigenesis and metastasis.
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Figure 2. 
Expression of PKCε in prostate cancer. (a) In silico PKCε mRNA expression profiling in 81 
normal/normal adjacent prostate tumors, 48 primary prostate carcinomas and 25 prostate 
cancer metastasis obtained from a publicly available dataset (GSE6919). PRKCE, PKCε 
gene. (b) Meta-analysis of PRKCE mRNA expression across 16 prostate microarray studies 
from the Oncomine database. This meta-analysis shows non-statistically significant 
differences in PRKCE mRNA expression (combined p-value=0.41) between normal and 
prostate cancer groups. Red intensity is a representative of the statistical significance in 
mean difference between normal and protate cancer for each study. (c) Expression of PKCε 
in “normal” immortalized prostate epithelial RWPE-1 cells vs. prostate cancer cells. This 
figure was originally published by Garg R, Blando J, Perez CJ, Wang H, Benavides FJ, and 
Kazanietz MG. in J Biol Chem. 2012 287:37570–37582, © The American Society for 
Biochemistry and Molecular Biology.
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Figure 3. 
Loss of PKCα gene enhances tumor progression. (a) Deletion of the PKCα gene enhances 
the formation of tumors in APCMin/+ mice, and those tumors show a more aggressive 
phenotype. (b) Deletion of PKCα in K-Ras mutant mice resulted in progression of benign 
tumors to adenocarcinoma. Tumors exhibit high frequency and grade, and are bigger in size.
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Figure 4. 
Multiple biological functions regulated by PKCδ. Studies in cellular models established 
important roles for PKCδ in apoptosis and as a negative regulator of cell cycle progression. 
PKCδ has been also implicated in cancer cell motility and invasiveness. Studies using 
animal models showed that PKCδ can either act as a tumor suppressor or contribute to 
tumorigenesis depending on the context.
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Figure 5. 
Phenotype of prostate-specific PKCε transgenic mice. Prostate-specific overexpression of 
PKCε in mice under the control of the probasin (PB) promoter leads to a preneoplastic 
phenotype. Representative photomicrographs for H&E, phospho-Akt, phospho-NF-κB and 
phospho-Stat3 staining in ventral prostates from 12-month old male PB-PKCε mice are 
shown.
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Figure 6. 
Roles of atypical PKCs in cancer. Most evidence points to PKCζ as a tumor suppressor 
protein and PKCι as an oncogenic kinase.
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